NYMC Faculty Publications
Therapy for Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma in Children, Adolescents, and Young Adults
Author Type(s)
Faculty
DOI
10.6004/jnccn.2024.7006
Journal Title
JNCCN Journal of the National Comprehensive Cancer Network
Document Type
Article
Publication Date
7-1-2024
Department
Pediatrics
Disciplines
Medicine and Health Sciences
Abstract
Despite excellent cure rates among children, adolescents, and young adults (CAYAs) with mature B-cell non-Hodgkin lymphomas (B-NHLs) treated with chemoimmunotherapy, CAYAs with relapsed/refractory B-NHL remain difficult to treat, with a dismal prognosis. Reinduction and subsequent therapeutic management are not standardized. The armamentarium of active agents against B-NHL, including antibody–drug conjugates, monoclonal antibodies, checkpoint inhibitors, T-cell engagers, CAR T cells, CAR-natural killer (CAR-NK) cells, and cell signaling inhibitors, continues to expand. This article reviews current management practices and novel therapies in this difficult to treat population.
Recommended Citation
Gardenswartz, A., & Cairo, M. (2024). Therapy for Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma in Children, Adolescents, and Young Adults. JNCCN Journal of the National Comprehensive Cancer Network, 22 (5). https://doi.org/10.6004/jnccn.2024.7006
